Suppr
超能文献

HIV阳性与肛门癌结局：单中心经验

HIV positivity and anal cancer outcomes: A single-center experience.

作者信息

Wieghard Nicole, Hart Kyle D, Kelley Katherine, Lu Kim C, Herzig Daniel O, Mitin Timur, Thomas Charles R, Tsikitis Vassiliki Liana

机构信息

Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR 97239, USA.

Department of Radiation Oncology, Oregon Health & Science University, Portland, OR, USA.

出版信息

Am J Surg. 2016 May;211(5):886-93. doi: 10.1016/j.amjsurg.2016.01.009. Epub 2016 Feb 23.

DOI:10.1016/j.amjsurg.2016.01.009

PMID:26988618

Abstract

BACKGROUND

Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status.

METHODS

We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival.

RESULTS

HIV+ patients were more often male (100% vs 38%, P < .001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36% vs 86%, P < .001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57).

CONCLUSIONS

HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.

摘要

背景

肛管癌在人类免疫缺陷病毒（HIV）感染者中仍然很常见。放化疗的效果不一。我们评估了不同HIV状态患者的预后差异。

方法

我们回顾性分析了14例HIV阳性和72例HIV阴性的肛管癌患者（2000年至2013年）。预后指标包括放化疗耐受性、复发率和生存率。

结果

HIV阳性患者男性比例更高（100%对38%，P <.001），但诊断时分期相似（P =.49）。他们接受传统化疗的可能性较小（36%对86%，P <.001）。两组的复发率（P =.55）和生存时间（P =.48）相似。HIV阳性患者的无结肠造口生存率相似（P =.053）。接受5-氟尿嘧啶/丝裂霉素C（MMC）化疗可预测无复发生存率和总生存率（风险比分别为.278、.32）。HIV状态并不会使复发率（P =.71）或生存率（P =.57）恶化。